⁸⁹ Zr-ImmunoPET companion diagnostics and their impact in clinical drug development.

ABSTRACT: Therapeutic monoclonal antibodies have been used in cancer treatment for 30 years, with around 24 mAb and mAb:drug conjugates approved by the FDA to date. Despite their specificity, efficacy has remained limited, which, in part, derails nascent initiatives towards precision medicine. An image-guided approach to reinforce treatment decisions using immune positron emission tomography (immunoPET) companion diagnostic is warranted. This review provides a general overview of current translational research using Zr-89 immunoPET and opportunities for utilizing and harnessing this tool to its full potential. Patient case studies are cited to illustrate immunoPET probes as tools for profiling molecular signatures. Discussions on its utility in reinforcing clinical decisions as it relates to histopa

SUBMITTER: McKnight BN 

PROVIDER: S-EPMC6050145 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature